D. E. Shaw & Co., Inc. Vaxcyte, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 867,891 shares of PCVX stock, worth $32.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
867,891
Previous 775,653
11.89%
Holding current value
$32.3 Million
Previous $63.5 Million
48.39%
% of portfolio
0.03%
Previous 0.05%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
345Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$453 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$448 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$438 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$370 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$239 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.21B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...